2026-526135-18-00RecruitingPhase 1
A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Aug 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 27 Mar 2026
- Start date
- 12 May 2026
- Lead sponsor
- Vicore Pharma AB
- EU CT number
- 2026-526135-18-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 years. The record lists idiopathic pulmonary fibrosis as the condition and says healthy volunteers can join.
- Age
- 18 to 64 years
- Sex
- Men and women can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CTC Clinical Trial Consultants AB | Uppsala | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.